An investigation of the relationship between CCND1 amplification and ICI treatment response rate reported a significantly shorter OS, especially in urothelial carcinoma (HR = 3.6) and melanoma (HR = 1.6–2.5) [34,35]. Here, CCND1 is linked to melanoma.